Nunavut's top doctor says early testing and awareness key to eliminating TB
Chief Public Health Officer Dr. Ekua Agyemang spoke with the CBC's Natsiq Kango about the success in the two communities and how people in Arviat and Naujaat can continue to manage ongoing TB outbreaks in those communities.
This interview has been edited for length and clarity.
How are you feeling about declaring TB outbreaks over in Pangnirtung and Pond Inlet?
It's really exciting. I feel proud to have had the privilege to work alongside the leadership of Pond Inlet and Pangnirtung over the past two years to bring us to this point in time. The communities of Pond Inlet and Pangnirtung have worked really, really hard to come to this point where for about two years they have not had a new case of tuberculosis that is infectious in any of these communities.
What do you think was effective in bringing down those cases?
It's about people understanding what this was about and overcoming the fear and stigma that we inherited from TB sanitoriums, and colonialism, and coming together to understand that if we found TB early, it could be treated in communities.
And how has all this affected the staff?
Over the past four years for Pangnirtung and about two years for Pond Inlet, it's been a lot of hard work. We've had several nurses come in and out of communities to support screening. But much more importantly, what really worked in these communities were the community health representatives who lived in the community, who knew the people, who went on radio and spoke about TB and helped to break down the stigma, who built trust and relationships, who encouraged people who needed to take their medication.
It is the hard work and diligence of these community members and the duty workers, people who help other people to take their medication as well as people who were doing those home visits and the leadership of the communities.
How many outbreaks are active in other communities?
We still have a TB outbreak in Arviat, and Naujaat, and we are working really hard. We are hopeful that sometime soon we can come to this point where we can be confident to close the outbreaks in those communities as well.
What should Nunavummiut continue to do, to eliminate TB in the territory?
Early identification and treatment. The symptoms of TB are coughing for more than two weeks, weight loss, loss of appetite. If we find TB early, we do not have to send anybody out like was done in the past. If people have sleeping TB, sometimes they will not have a cough, they will not have any sign or symptom, they will not feel sick.
The other factors like housing, food security, education and awareness to bring down the stigma and the fear around TB.
What's the level of concern that you have for continued spread of TB in Naujaat and Arviat?
TB is not actively spreading there.
The outbreak is ongoing because we are still in the process of giving everyone in Naujaat and Arviat the opportunity to know their TB status through screening.
If you have sleeping TB, you take care of it so that it never wakes up.
What is the health department doing to remove barriers to testing and treatment?
I believe that the first barrier is availability and access, so we are working hard to make sure that communities have public health nurses who are qualified to be able to identify a test and treat TB. But the most significant thing is being able to treat it in community and identifying it early.
Inuit Tapiriit Kanatami and the federal government are aiming to eliminate TB by 2030. What do you believe needs to happen to reach that goal?
Actions today will determine if 2030 will be possible or not. Like I said, early identification is key when it comes to elimination of TB and treatment, which means that people taking their medication, but also creating the environment and enabling people to be able to do that.
So, pediatric medication that would be easy for the children who have, say, sleeping TB to take. Education and awareness is also a great thing.
Teaching community members, teaching health-care workers, so all health-care workers, doctors, nurses, everyone knowing the signs and symptoms and thinking about TB at all times. Then as soon as someone comes and we suspect it could be TB, we could easily find and treat the person and they don't have to continue living in community and spreading when they don't know.
Moving to a different illness, pertussis, or whooping cough, outbreaks . What would you like to share with Iqaluit and Pond Inlet residents on that?
The main thing we must understand is that pertussis is a vaccine-preventable disease, which means that if people are immunized, they do not get pertussis. We are seeing pertussis because we have pockets of people who are not immunized.
It is those who are not immunized or up to date, they haven't gotten the complete series of immunization for pertussis who are getting it. Let's think about other people, especially the babies who are not yet eligible to take the pertussis vaccine.
Pertussis is first given at two months, to a baby. So all babies less than two months, they will not have had opportunity to take the pertussis vaccine and are at very high risk.
For adults, they can help pertussis. It might not be deadly, but let's think about the babies and the children and let's get immunized so that we can protect their lives because they are the ones who really suffer, as well as our elders.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Not Tonight, Honey... I'm Allergic to Your Spunk
Allergic reactions to semen are, unfortunately, very real. In an essay for The Conversation, reproductive science specialist Michael Carroll of the UK's Manchester Metropolitan University explained that allergic reactions to seminal fluid can manifest as a nasty response to a partner's ejaculate, or even your own. The most common semen allergy is what's known as "seminal plasma hypersensitivity" or SPH, in which women who have sex with men react to proteins in seminal plasma, the goopy stuff that makes up spunk. In other words, it's the seminal fluid that's to blame, not the sperm itself — but the symptoms are very real, ranging from irritating vulvar itching and painful vaginal burning to anaphylactic shock. Bottom line? A lot of people might be suffering from this and not even know it. If you might be, doctors recommend either using condoms, taking antihistamines before sex, taking anti-inflammatory medications after sex, or desensitization therapy involving exposure of diluted semen to the skin. "If sex routinely leaves you itchy, sore or unwell — and condoms help — you might be allergic to semen," Carroll wrote. First documented nearly 60 years ago when a woman had to be hospitalized for her "violent allergic reaction" to sex, SPH is still, the reproductive expert wrote, often underdiagnosed. Until the year 1997, the medical establishment thought that fewer than 100 women had ever experienced the allergy, but a seminal — sorry — study that year found that nearly 12 percent of postcoital illnesses could be attributed to SPH. (Regrettably, there does not appear to be any formal inquiry whether men who have sex with men can have SPH, though there does appear to be anecdotal evidence that it does.) About 15 years later, Carroll conducted an informal survey that found the same rate of probable SPH, though he found that the cases had often gone misdiagnosed as sexually transmitted illnesses, yeast infections, or even run-of-the-mill "sensitivity." Given that its symptoms mirror some of those illnesses, it's not hard to see why. Along with being allergic to one's partner's semen, a separate condition known post-orgasmic illness syndrome (POIS) affects men who are allergic to their own skeet. With only 465 documented cases as of 2024, POIS can cause flu-like symptoms like fatigue and muscle aches immediately after ejaculation — and doctors are stumped as to its cause. Like SPH, both antihistamines and desensitization are recommended for POIS, as is hormonal therapy. Speaking about SPH specifically, Carroll noted that more often than not, "sex-related symptoms often go unspoken." "Embarrassment, stigma, and a lack of awareness among doctors mean that many women suffer in silence," the reproductive scientist said. More on weird sex stuff: Hanky Panky With Naughty AI Still Counts as Cheating, Therapist Says
Yahoo
2 hours ago
- Yahoo
2 Stocks to Buy on the Dip and Hold for 10 Years
Novo Nordisk's shares look attractive after a terrible performance over the past 12 months. DexCom has significant room to grow in its core market, despite disappointing results last year. 10 stocks we like better than Novo Nordisk › One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities. Two great examples today in the healthcare sector are Novo Nordisk (NYSE: NVO) and DexCom (NASDAQ: DXCM). Although these two corporations have encountered significant headwinds since last year, they could deliver market-beating returns to investors who initiate positions today and stick with them for at least a decade. Novo Nordisk is coming off clinical setbacks and unimpressive financial results, at least by its lofty standards. The stock has significantly underperformed the market over the trailing-12-month period. But after this beating, the company's shares look attractive. Here are several reasons why. First, although Novo Nordisk's eternal rival, Eli Lilly, appears to be taking the lead in the fast-growing weight management market, the former still has excellent prospects in this rapidly expanding therapeutic area. Novo Nordisk's Wegovy continues to grow its sales at a good clip, and the company is awaiting approval from the U.S. Food and Drug Administration for an oral formulation of this popular medicine. Further, Novo Nordisk has promising internally developed pipeline candidates, such as amycretin, which recently entered phase 3 studies. The Denmark-based drugmaker has also enhanced its pipeline in this area, thanks to licensing deals and acquisitions. Second, Novo Nordisk has been working on diversifying its lineup and currently has promising pipeline candidates outside of its core treatment areas of diabetes and obesity. Novo Nordisk is developing medicines for conditions including hemophilia, Parkinson's disease, sickle cell disease, Alzheimer's disease, and others. Third, after being southbound for the past 12 months, Novo Nordisk's shares look reasonably valued. The company's forward price-to-earnings ratio is 16.8, compared to the 16.3 average for the healthcare industry. Novo Nordisk's financial results over the past year have been terrific by industry standards, but not quite what the market expected. That may have justified the sell-off, but at current levels, the stock looks attractive. Finally, Novo Nordisk is a solid dividend-paying company. It has increased its annual dividend per share by almost 284% over the past decade, while offering a forward yield of 2.3%. That's not exceptional, but it's above the S&P 500 index's average of 1.3%. Novo Nordisk is well-positioned to bounce back and deliver strong returns in the next decade as it rides weight management (and other) tailwinds. DexCom is a leading diabetes-focused medical device company. It develops continuous glucose monitoring (CGM) systems that help diabetics with constant blood sugar level measurements. DexCom has been successful thanks to the increased adoption of this innovative technology. Unlike blood glucose meters that are manually operated, use pesky and painful fingersticks, and can only tell a person's sugar level at one point in time, CGM devices are constantly monitoring things and automatically make measurements as often as every five minutes. Rrevenue and earnings have grown rapidly over the past decade, but the company hit a speed bump last year when its top-line growth slowed considerably, partly due to higher-than-expected rebates in the U.S., resulting in lower revenue per patient. That said, these are short-term issues that do little to impact the company's long-term prospects. And on that front, there are still plenty of reasons to be excited about DexCom's future. Consider that the company has ample room to grow, even in the U.S., a country that enjoys higher CGM penetration than most others. However, as DexCom has consistently pointed out, the population of patients who use CGM continues to lag behind those who are eligible for third-party coverage -- in other words, many people could obtain the technology paid for by insurers but have not yet opted in. Further, there is a vast worldwide opportunity, since only a tiny percentage of the diabetics in the world use CGM technology. Though many are in countries where DexCom does not do business, the company has generally increased its addressable market by entering new geographies. In the next 10 years, expect the company to do the same while benefiting from greater insurance coverage for CGM -- third-party payers, including governments, have been more willing to foot the bill because of the technology's benefits. All that should lead to consistent revenue and earnings growth for the medical device specialist. The stock has crushed the market in the past decade using this formula. In my view, it is well-positioned to do the same through 2035. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. 2 Stocks to Buy on the Dip and Hold for 10 Years was originally published by The Motley Fool
Health Line
3 hours ago
- Health Line
Rob Lowe Wants More People to Join Cancer Clinical Trials. Here's Why
Rob Lowe shares how three generations of women in his family passed away from breast cancer. The acclaimed actor has partnered with Eli Lilly to spread awareness about the benefits of cancer clinical trials. Lowe's grandmother benefited from participating in two clinical trials for breast cancer. Iconic actor Rob Lowe credits his grandmother, Mim, for his love of reading. 'My earliest memories are her reading me my favorite book, 'Peter Rabbit,' while she sipped her Sanka,' he told Healthline. 'I always wanted to have my own coffee, so she would make me a cup of milk and then put a little drop of Sanka in it so it would look like coffee.' When he was 10 years old, Mim was diagnosed with breast cancer, the same disease her mother had endured. 'It was almost a death sentence,' Lowe said. Following her diagnosis, Mim underwent a bilateral mastectomy, the standard of care at the time, which can significantly impact quality of life. While double or bilateral mastectomy rates have declined in recent years, some people still require the surgery. After a cancer recurrence, Mim entered a clinical trial, which Lowe said extended her life. Years later, she participated in a second clinical trial. 'Both times had tremendous, tremendous success, and it was a very pivotal moment in my upbringing that I always remember,' he said. Following his grandmother's diagnosis, Lowe's mother was also diagnosed with breast cancer. He said her standard of care was an improvement compared to his grandmother's. 'There are amazing advances in medicine, particularly breast cancer, and what I've seen going through this three times is tremendous enhancements,' Lowe said, noting the impact clinical trials have had on cancer treatments. Now, Lowe wants more people to participate in clinical trials. Only around 7% of U.S. cancer patients join clinical trials, limiting their access to potential breakthroughs and delaying new medications from helping others. In honor of the three generations of women he lost to breast cancer, Lowe teamed up with Eli Lilly to bring awareness to the urgent need for more people to participate in cancer clinical trials. 'I thought this was a great way to remember and keep my grandma Mim's memory alive,' he said. Clinical trials offer hope to people with cancer. For instance, a new breast cancer vaccine is showing effectiveness in clinical trials at preventing and treating breast cancer. The vaccine works by training the immune system to recognize and eliminate cancerous cells before they develop into invasive tumors. 'Participating in a trial can provide access to cutting-edge drugs that are not yet on the market, improve quality of life, and advance science. The trials of today are the treatments of tomorrow,' Davendra Sohal, MD, associate director for Clinical Research at the University of Cincinnati Cancer Center, told Healthline. Clinical trials are used for all types and stages of breast cancer. People can join any phase of a trial if they meet the criteria, which is based on multiple factors, including type of disease, age, medical history, and current medical condition. However, barriers to clinical trials prevent many people from enrolling. These include: certain beliefs or lack of trust distance to trial sites insufficient health insurance coverage language barriers immigration status In addition to barriers, new treatments developed in clinical trials face a long road before they're approved for use in the real world. 'New treatments are studied for lengthy periods of time, typically years, before they receive FDA approval,' Irene M. Kang, MD, medical director of women's oncology at City of Hope Orange County, told Healthline. 'This is why clinical trials are critical for studying new drugs, medical devices, products, and additional treatments before they may become standard of care.' If you want to know more about clinical trials, Lowe encourages you to ask your doctor. '[There's] so much hope out there, and it's not an end-of-the-road ask. If it's the beginning of the road, ask your doctor,' he said. Healthline spoke with Lowe to learn more about the women in his life who were diagnosed with breast cancer and his passion for participating in clinical trials. This interview has been edited and condensed for clarity and length. Did your grandmother's experience with clinical trials impact your views on medicine? Lowe: Yes. Particularly as she got into the second one, where I was much older and really able to understand it more clearly. We were very fortunate to have the experience of watching the miracle of progress in medicine unfold in real time with real results. Obviously, not everyone has that result, but we did, and that's where I've gotten my lifelong interest in cancer patient advocacy from, because of our experience. I remember the treatments that were horrifying for my grandma… and then with my mother, it was a completely different experience a decade later. The exponential rate of new technology is truly a marvel, and now with AI, it will be more unbelievable. How did having three women in your family die from breast cancer affect you? Lowe: The new [genetic] tests were not available for them. My brother Chad has three daughters, so they will be getting the test, and I will make sure of it. Family history is a big deal. Know your family history. Information and asking questions are as critical as any treatment you're going to get. Be diligent. What would you say to those who are wary of clinical trials? Lowe: My number one thing is that all patients have to advocate for themselves. It is the number one game changer in the path you have ahead of you — your ability to advocate, to ask questions, to champion, and guide your own recovery is critical. Doctors are only as good as the information they get and the questions that they're asked. One of them that a lot of people don't ask is: Is there a clinical trial that can be helpful for me? It's very simple. Less than 7% of patients do it. That number needs to be much, much, much higher. I would also add that I think one of the reasons that there's some [hesitation] is that I think people feel like 'well, if I'm in a clinical trial, maybe I'm going to get a placebo and I actually want treatment.' Well, in cancer clinical trials, you get the standard of care. You're not going to not get the standard of care. You may get a cutting-edge new care in addition, and to me, that's a no-brainer. Is it rewarding to work with Eli Lilly to spread awareness about something so personal? Lowe: I do find it really rewarding and, more than anything, inspiring. You get inspired by both the patient's journey, which is always a journey of courage, and by having a front-row seat with a company like Lilly, where you see the strides being made that make me so hopeful for the future; it's something I get a lot out of personally. What inspires you to talk about health? Lowe: One's health is the great equalizer, as we all know, and nothing reminds you of your humanity more than the frailty of our health and the importance that we all have of doing the best that we can for ourselves in that area. It does keep you connected to your fellow human beings. Have your views on health changed as you've gotten older? Lowe: I've been fortunate that I've always kept it [a priority] since my early 20s when I stopped drinking and had a very healthy path of recovery and mental healthcare. I was kind of early to the party and stayed the course, and it's been unbelievably beneficial to me as I've gotten older. [Now, I] offer that advice, as I can, even to my sons, who are in their early 30s.
